GRAIL grants equity awards to 59 non-executive employees

SUNNYVALE, Calif., Sept. 3, 2026 /CourierPR/ -- GRAIL, Inc., a company dedicated to detecting cancer early to improve curability, has granted equity awards to 59 recently hired non-executive employees. These inducement grants, totaling 55,867 shares of restricted stock units (RSUs) under the company's Inducement Equity Incentive Plan, are designed to incentivize these employees to join GRAIL's workforce.

According to the announcement, the RSUs will vest over a four-year period, with 25% of the total grant vesting on August 31, 2027, and the remainder vesting annually thereafter, contingent on the employees' continued employment with GRAIL or any of its subsidiaries.

"This strategic move aligns with our mission to support the early detection of cancer and enhance patient outcomes," said Sarah Lee, GRAIL's Chief People Officer. "These inducement awards are a key part of our efforts to attract and retain top talent as we continue to advance our innovative cancer detection technologies."

GRAIL's mission is to alleviate the global burden of cancer through the application of next-generation sequencing, population-scale clinical studies, and advanced machine learning and automation. The company's platform is designed to detect and identify multiple deadly cancer types at earlier stages, supporting the continuum of care from screening to precision oncology.

"By offering these inducement grants, we are not only attracting talented individuals but also reinforcing our commitment to driving innovation in the field of cancer detection," added Lee.

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for the granting of equity awards to new hires as an inducement to employment. GRAIL's Inducement Equity Incentive Plan is specifically designed to provide such inducements, ensuring that the company can attract key personnel in the highly competitive biotech industry.